Preclinical AD predicts decline in memory and executive functions in subjective complaints

Abstract

CSF evidence of preclinical AD in patients with subjective complaints predicted cognitive decline over time, encompassing more than memory alone. Executive functioning and global cognitive functioning also deteriorated. On the other hand, 2-year prognosis for patients without evidence of AD pathophysiology was good.

Factors that predict cognitive decline in patients with subjective cognitive impairment

“…A study by van Harten et al (2013) found that CSF biomarker evidence of preclinical AD in patients with SCI predicted cognitive decline over time. No CSF or imaging biomarkers were available in the present study.…”

Suspected non-Alzheimer disease pathophysiology — concept and controversy

“…Different methods were used to classify the participants in these studies (see Supplementary Table online). Some studies used imaging alone, 1,8–11 others CSF biomarkers alone, 12–14 others CSF biomarkers combined with imaging. 15 The proportion of individuals with SNAP among clinically normal participants aged >65 years was very consistent across these studies, many of which, perhaps coincidently, reported exactly 23% (see Supplementary Table online).…”

Does Alzheimer Disease Pathologic Change Underlie Subjective Cognitive Complaints?

“…The subsequent decline may ultimately meet diagnostic criteria for mild cognitive impairment or dementia, and risk of such progression may be increased among carriers of the apolipoprotein E (APOE) ε4 allele 1 and those with biomarker evidence supporting the diagnosis of Alzheimer’s disease (AD). 2 …”